Full Press Release Details
Anika Therapeutics Appoints Orthopedics Veteran
John C. Moran to Board Of Directors
Mass., Dec. 14 /PRNewswire-FirstCall/ Anika Therapeutics, Inc. (Nasdaq: ANIK)
today announced that it has appointed John C. Moran as a new independent
director on the Company s Board of Directors. Mr. Moran succeeds Dr. Harvey
Sadow, who has retired from the board.
Moran s 25 years of executive management experience in the orthopedics and
spinal implant industries will be a valuable asset to Anika s board as well as
a strategic asset to the Company, said Charles H. Sherwood, Ph.D., president
and chief executive officer. We welcome John to the board and look forward to
benefiting from his participation going forward.
want to acknowledge Dr. Harvey Sadow s contributions to Anika since he joined
the board in 1995, said Sherwood. Harvey s guidance has been invaluable, and
we are a stronger enterprise because of his efforts. We wish him well on his
formerly served as the first president of Synthes Spine, a division of Synthes
(USA), the leading skeletal fixation company in the world. Synthes Spine
designs, manufactures and distributes implants and instruments for spinal
disorders. During Mr. Moran s six-year tenure as president of Synthes Spine,
sales grew from less than $1 million to more than $60 million annually. Since
leaving Synthes in 1997, Mr. Moran has been a private investor in a number of
companies, mostly in the medical device field.
is a graduate of the University of Notre Dame, and holds a master s degree in
business administration from Harvard Business School. He currently serves on
the boards of PowerMedical Interventions, Inc., Christini Technologies,
Paradigm Spine, LLC and Ranier Technologies.
Anika Therapeutics, Inc.
in Woburn, Mass., Anika Therapeutics, Inc. (http://www.anikatherapeutics.com)
develops, manufactures and commercializes therapeutic products for tissue
protection, healing and repair. These products are based on hyaluronic acid
(HA), a naturally occurring, biocompatible polymer found throughout the body.
Anika products include OrthoVisc , a treatment for osteoarthritis of the
knee available internationally and marketed in the U.S. by DePuy Mitek, and
Hyvisc , a treatment
for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim
Vetmedica, Inc. Anika manufactures AmviscTM and Amvisc PlusTM, HA viscoelastic products for
ophthalmic surgery. It also produces STAARVISCTM-II, which is distributed by STAAR
Surgical company and ShellgelTM for Cytosol Ophthalmics, Inc.
Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., CEO
Kevin W. Quinlan, CFO